A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia

Trial Profile

A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia

Completed
Phase of Trial: Phase II/III

Latest Information Update: 25 Aug 2015

At a glance

  • Drugs Cariprazine (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 25 Aug 2015 According to an Allergan media release, pooled data from phase II/III studies will be presented at the 28th European College of Neuropsychopharmacology (ECNP) annual congress.
    • 28 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 22 Jan 2014 Status changed from recruiting to active, no longer recruiting ar reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top